kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified), 100µg  

Recombinant Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified), 100µg

Recombinant Mouse CD86 /B7-2 Protein (Mouse CD86 Fc Chimera) Val 24 - Glu 245 was produced in human 293 cells (HEK293), Fc Tag (MALS verified)

Synonym: recombinant, mouse, protein, CD86, B7-2, B70 ,CD28LG2, LAB72, MGC34413

More details


Availability: within 7 days

234,00 €

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Recombinant Mouse CD86/B7-2, Fc Tag (CD6-M5251) is expressed from human 293 cells (HEK293). It contains AA Val 24 - Glu 245 (Accession # NP_062261.3).
Predicted N-terminus: Val 24

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.9 kDa. The protein migrates as 66-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A"
Ayass, Tripathi, Griko et al
Cancers (Basel) (2024) 16 (5)
(2) "Co-stimulatory pathway competitive assay development using Liquid chromatography-tandem mass spectrometry (LC-MS/MS)"
Malkawi, Ohlund, Rahman et al
J Pharm Biomed Anal (2024) 242, 116034
(3) "Immunopotentiating effects of herb-partitioned moxibustion on the spleens of cyclophosphamide-induced immunosuppressed rats"
Xiong, Tian, Xu et al
Chin Med (2024) 19 (1), 28
Showing 1-3 of 4794 papers.